Hospital
Hampton Regional Medical Center
Hampton Regional Medical Center was paid $6.15M by Medicaid between Jan 2018 and Nov 2024, across 114 billing codes. Its largest line is 87502, Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets — 17% of everything it billed.
33Billing provider infoHAMPTON REGIONAL MEDICAL CENTER
VARNVILLE, SC 29944
VARNVILLE, SC 29944
33aNPI1487651949assigned 06/30/2005
33bProvider typeRural Acute Care Hospital
28Total paid$6.15M
24GClaims209,952
24DCodes billed114
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in South Carolina
Rank by total paid#3 of 5
Median peer was paid$6.15M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 29,992 | $930K | |
| 2019 | 30,830 | $977K | |
| 2020 | 24,999 | $714K | |
| 2021 | 29,378 | $749K | |
| 2022 | 32,911 | $856K | |
| 2023 | 35,839 | $1.08M | |
| 2024incomplete | 26,003 | $847K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 17% | 4,401 | 4,095 | $1.07M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 23,231 | 21,457 | $1.03M |
| 36415 | Collection of venous blood by venipuncture | 12% | 13,900 | 9,667 | $744K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 11% | 11,029 | 10,225 | $689K |
| 80053 | Comprehensive metabolic panel | 9.2% | 11,440 | 8,886 | $566K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.1% | 12,910 | 11,598 | $373K |
| 81001 | 4.0% | 9,887 | 8,483 | $247K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.4% | 7,983 | 2,170 | $210K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.8% | 3,212 | 2,798 | $173K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.0% | 4,531 | 4,001 | $122K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 3,908 | 3,014 | $106K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.5% | 959 | 870 | $92K |
102 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 2,425 | $79K |
| 81025 | 1.1% | 3,927 | $66K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 554 | $64K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,425 | $57K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,776 | $51K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,257 | $50K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,593 | $37K |
| 73562 | <1% | 500 | $34K | |
| 80305 | <1% | 1,888 | $31K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 857 | $27K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,872 | $26K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,583 | $20K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 173 | $15K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,143 | $13K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,307 | $12K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 102 | $11K |
| 73630 | <1% | 150 | $10K | |
| 86756 | <1% | 742 | $10K | |
| 81003 | <1% | 177 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,831 | $7K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,220 | $6K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 204 | $5K |
| 85027 | <1% | 762 | $5K | |
| 73610 | <1% | 41 | $5K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,264 | $5K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 907 | $4K |
| 73130 | <1% | 45 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 225 | $4K |
| 83735 | <1% | 2,618 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,484 | $3K |
| 74018 | <1% | 130 | $3K | |
| 87040 | <1% | 1,969 | $3K | |
| 97162 | <1% | 107 | $3K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 53 | $3K |
| G0378 | Hospital observation service, per hour | <1% | 342 | $3K |
| 82553 | <1% | 2,949 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,230 | $3K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 160 | $2K |
| 82550 | <1% | 1,357 | $2K | |
| 83690 | <1% | 2,884 | $2K | |
| 85610 | <1% | 662 | $2K | |
| 73030 | <1% | 29 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,454 | $2K |
| 97161 | <1% | 89 | $2K | |
| 99223 | Prolong inpt eval add15 m | <1% | 16 | $2K |
| 85379 | <1% | 801 | $1K | |
| 80061 | Lipid panel | <1% | 582 | $1K |
| A9270 | Non-covered item or service | <1% | 8,616 | $1K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 29 | $1K |
| 87210 | <1% | 15 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 62 | $1K |
| 72100 | <1% | 46 | $949.15 | |
| 84484 | <1% | 3,815 | $923.83 | |
| 80320 | <1% | 397 | $828.70 | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 17 | $823.63 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,060 | $812.84 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,556 | $698.17 |
| 72020 | <1% | 13 | $605.72 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 39 | $538.55 |
| 36000 | <1% | 14 | $434.48 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 30 | $397.01 |
| 86900 | <1% | 13 | $392.03 | |
| 87070 | <1% | 13 | $318.86 | |
| 83880 | <1% | 987 | $313.88 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 18 | $258.77 |
| 83605 | <1% | 2,156 | $247.76 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,074 | $234.59 |
| 86140 | <1% | 458 | $158.99 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,163 | $154.11 |
| 87088 | <1% | 615 | $133.92 | |
| 84439 | <1% | 149 | $112.35 | |
| 94760 | <1% | 672 | $80.76 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 175 | $10.11 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 105 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 17 | $0.00 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 18 | $0.00 |
| 84100 | 0% | 35 | $0.00 | |
| 82570 | 0% | 41 | $0.00 | |
| 87185 | 0% | 127 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 41 | $0.00 |
| 80299 | 0% | 28 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 641 | $0.00 |
| 87184 | 0% | 999 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 296 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 18 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 550 | $0.00 |
| 85730 | 0% | 808 | $0.00 | |
| Q3014 | Telehealth originating site facility fee | 0% | 18 | $0.00 |
| 85018 | 0% | 14 | $0.00 | |
| 96361 | Intravenous infusion, hydration; each additional hour | 0% | 166 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 182 | $0.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 43 | $0.00 |
| 82150 | 0% | 31 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 19 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 42 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 82 | $0.00 |
| 81015 | 0% | 36 | $0.00 | |
| 87081 | 0% | 69 | $0.00 | |
| 82044 | 0% | 14 | $0.00 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 28 | $0.00 |
| 86901 | 0% | 13 | $0.00 | |
| 82607 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHAMILL, DAVE (CEO)
| Provider | Location | Paid |
|---|---|---|
| Coastal Plains Physician Associates | Varnville, SC | $213K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.